Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival.
The company said its Darzalex (daratumumab) also significantly increased the overall response rate in Phase III study.
Jane Griffiths, company group chairman, Janssen Europe, Middle East and Africa, said: “The findings provide an important insight into the effect daratumumab can have in combination with established regimens, and illustrate the promise of this immunotherapy in earlier lines of treatment.”
Darzalex was studied in combination with bortezomib (a proteasome inhibitor [PI]) and dexamethasone (a corticosteroid).
Antonio Palumbo, myeloma unit chief, department of oncology, division of haematology, University of Torino, Italy, said: “We saw clinically meaningful improvements in progression-free survival and overall response rates with daratumumab when combined with standard of care. These compelling Phase III results demonstrate that a regimen built on daratumumab deepens clinical responses and help to underscore its potential for multiple myeloma patients who have been previously treated.”
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …